Monoclonal Antibodies Market Size & Share Report, 2029

Comments · 86 Views

The size of global monoclonal antibody therapeutics market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029.

The monoclonal antibody therapeutics market is poised for robust growth, with the market projected to reach USD 497.5 billion by 2029 from an estimated USD 252.6 billion in 2024. This represents a compound annual growth rate (CAGR) of 14.5% during the forecast period. The growth of this market is driven by the increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases, as well as advancements in antibody engineering and production processes.

Download PDF Brochure:

Market Segmentation and Trends

Production Method

The monoclonal antibody therapeutics market is segmented based on production methods into in vitro and in vivo. In 2023, in vitro production accounted for the largest share of the market due to its scalability, cost-effectiveness, and lower risk of contamination compared to traditional in vivo methods. Additionally, advancements in cell culture and bioprocessing techniques have enhanced productivity and consistency.


Based on sources, the market is segmented into human, humanized, chimeric, and other sources. In 2023, the human segment accounted for the largest share of the market. The human source segment is expected to grow at a higher rate during the forecast period of 2024-2029 due to its reduced immunogenicity, improved efficacy, and enhanced safety profiles compared to non-human sources. Notable drugs include adalimumab (Humira) for autoimmune diseases and pembrolizumab (Keytruda) for cancer.

Therapy Areas

The market is segmented based on therapy areas into autoimmune and inflammatory disorders, oncology, hematology, ophthalmology, and other therapy areas. In 2023, the autoimmune and inflammatory diseases segment accounted for the largest share of the market, driven by the increasing prevalence of these diseases and advancements in targeted therapies. For instance, adalimumab (Humira) is widely used for treating rheumatoid arthritis, while infliximab (Remicade) is used for Crohn's disease.

Regional Insights

North America

North America dominated the monoclonal antibody therapeutics market due to its robust healthcare infrastructure and high prevalence of chronic diseases. The region is home to many leading pharmaceutical companies investing heavily in research and development.


Europe is expected to grow at a significant CAGR during the forecast period, driven by a combination of favorable government policies, research and development investments, and rising prevalence of chronic diseases. The region's strong healthcare infrastructure and collaborations between academia, industry, and regulatory bodies further contribute to its growth.

Asia Pacific

The Asia Pacific region is also expected to witness substantial growth during the forecast period due to rising healthcare spending, increased awareness about advanced therapies, and expanding access to healthcare services.

Key Market Players

The monoclonal antibody therapeutics market is characterized by the presence of leading players, including:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • AbbVie Inc. (US)
  • Johnson Johnson Services, Inc. (US)
  • Merck Co., Inc. (US)
  • Bristol Myers Squibb Company (US)
  • AstraZeneca (UK)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • Amgen Inc. (US)
  • Takeda Pharmaceutical Company Limited (Japan)
  • GSK plc. (UK)
  • Eli Lilly and Company (US)
  • Regeneron Pharmaceuticals Inc. (US)

These key players are focusing on expanding their product portfolios, engaging in strategic collaborations, and investing in research and development to maintain their competitive edge in the market.

Request Free Sample Pages:


The monoclonal antibody therapeutics market is set to experience strong growth in the coming years due to the increasing prevalence of chronic diseases, technological advancements, and expanding applications in personalized medicine. The future holds immense potential for this market, as innovations in antibody engineering and targeted therapies continue to advance patient outcomes across various medical conditions.

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441